Bellicum Pharmaceuticals logo
Bellicum Pharmaceuticals BLCM

Quarterly report 2023-Q3
added 11-14-2023

report update icon

Bellicum Pharmaceuticals Cost of Revenue 2011-2026 | BLCM

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Bellicum Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - 436 K 864 K - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
864 K 436 K 650 K

Quarterly Cost of Revenue Bellicum Pharmaceuticals

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - - - - - - - - - 173 K 30 K - 139 K 150 K 30 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
173 K 30 K 104 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
32.2 M - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
15.3 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
76 K - 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
1.36 M - -0.23 % $ 916 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
1.39 M $ 4.22 - $ 105 M schweizSchweiz
Aptorum Group Limited Aptorum Group Limited
APM
421 K $ 0.79 0.01 % $ 4.31 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
926 K - -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
100 K - - $ 86.2 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
3.52 M $ 231.03 2.23 % $ 5 B danmarkDanmark
BioCardia BioCardia
BCDA
4 K $ 1.27 - $ 26.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
90 K - 5.93 % $ 314 M canadaCanada
Catalyst Biosciences Catalyst Biosciences
CBIO
5.42 M $ 11.58 - $ 1.03 B usaUSA
Cerus Corporation Cerus Corporation
CERS
33.4 M $ 1.8 6.51 % $ 343 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
63.6 M $ 14.36 - $ 210 M usaUSA
BioNTech SE BioNTech SE
BNTX
2.91 B $ 90.54 - $ 27.2 B germanyGermany
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
4.74 M - - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
602 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
20.6 M $ 2.64 - $ 16.6 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
597 K $ 1.9 - $ 127 M usaUSA
CorMedix CorMedix
CRMD
22.1 M $ 6.54 - $ 471 K usaUSA